DaVita (NYSE:DVA) Updates FY 2025 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 10.200-11.300 for the period, compared to the consensus earnings per share estimate of 11.030. The company issued revenue guidance of -.

DaVita Stock Up 0.4%

Shares of DVA traded up $0.53 on Monday, hitting $144.29. The company’s stock had a trading volume of 1,275,522 shares, compared to its average volume of 820,697. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm’s fifty day moving average price is $145.85 and its 200-day moving average price is $153.83. DaVita has a fifty-two week low of $131.44 and a fifty-two week high of $179.60. The firm has a market capitalization of $11.09 billion, a price-to-earnings ratio of 13.43, a P/E/G ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA) last released its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping analysts’ consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities research analysts expect that DaVita will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on DVA shares. Barclays upped their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Finally, Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.